147 related articles for article (PubMed ID: 19572439)
1. [Lopinavir/ritonavir monotherapy as a simplification strategy in the treatment of HIV-1 infection].
Pulido Ortega F; Llenas-García J
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():12-20. PubMed ID: 19572439
[TBL] [Abstract][Full Text] [Related]
2. [The "induction-maintenance" strategy].
Arribas López JR
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():8-11. PubMed ID: 19572438
[TBL] [Abstract][Full Text] [Related]
3. [Lopinavir/ritonavir monotherapy as a simplification strategy in antiretroviral therapy in clinical practice].
Moltó J; Clotet B
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():24-6. PubMed ID: 19572441
[TBL] [Abstract][Full Text] [Related]
4. [Lopinavir/ritonavir monotherapy. Possible indications].
López Aldeguer J
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():21-3. PubMed ID: 19572440
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacoeconomic aspects of lopinavir/ritonavir monotherapy].
Escobar Rodríguez I; Esteban Alba C
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():47-51. PubMed ID: 19572445
[TBL] [Abstract][Full Text] [Related]
6. [Lopinavir/ritonavir monotherapy for the treatment of HIV-1 infection: the emergence of resistance].
Delgado R
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():34-40. PubMed ID: 19572443
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.
Simpson KN; Jones WJ; Rajagopalan R; Dietz B
Clin Drug Investig; 2007; 27(7):443-52. PubMed ID: 17563124
[TBL] [Abstract][Full Text] [Related]
9. [Monotherapy in treatment-naïve patients].
Arranz Caso JA
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():2-7. PubMed ID: 19572437
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy.
Pierone G; Mieras J; Bulgin-Coleman D; Kantor C; Shearer J; Fontaine L; Fath M; Norton M
HIV Clin Trials; 2006; 7(5):237-45. PubMed ID: 17162317
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic factors of virological response in patients treated with lopinavir/ritonavir monotherapy].
Pérez Valero I
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():27-33. PubMed ID: 19572442
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacoeconomic analysis of a maintenance strategy with lopinavir/ritonavir monotherapy in HIV-infected patients].
Escobar I; Pulido F; Pérez E; Arribas JR; García MP; Hernando A
Enferm Infecc Microbiol Clin; 2006 Oct; 24(8):490-4. PubMed ID: 16987465
[TBL] [Abstract][Full Text] [Related]
13. Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study).
Nunes EP; Santini de Oliveira M; Merçon M; Zajdenverg R; Faulhaber JC; Pilotto JH; Ribeiro JE; Norton M; Schechter M
HIV Clin Trials; 2009; 10(6):368-74. PubMed ID: 20133267
[TBL] [Abstract][Full Text] [Related]
14. [Positioning of lopinavir/ritonavir in antiretroviral treatment schemes].
Camacho Á; Rivero A
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():31-4. PubMed ID: 25542874
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Simpson KN; Luo MP; Chumney EC; King MS; Brun S
Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
[TBL] [Abstract][Full Text] [Related]
16. [Challenges of lopinavir/ritonavir in the chronicity of human immunodeficiency virus infection].
Aguirrebengoa K
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():26-30. PubMed ID: 25542873
[TBL] [Abstract][Full Text] [Related]
17. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks.
Molina JM; Podsadecki TJ; Johnson MA; Wilkin A; Domingo P; Myers R; Hairrell JM; Rode RA; King MS; Hanna GJ
AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1505-14. PubMed ID: 18160008
[TBL] [Abstract][Full Text] [Related]
18. Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.
Spire B; Marcellin F; Cohen-Codar I; Flandre P; Boue F; Dellamonica P; Raffi F; Norton M; Van Philippe N; Delfraissy JF
Antivir Ther; 2008; 13(4):591-9. PubMed ID: 18672538
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain.
Simpson KN; Jones WJ; Rajagopalan R; Dietz B
Clin Drug Investig; 2007; 27(12):807-17. PubMed ID: 18020538
[TBL] [Abstract][Full Text] [Related]
20. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
Pulido F; Arribas JR; Delgado R; Cabrero E; González-García J; Pérez-Elias MJ; Arranz A; Portilla J; Pasquau J; Iribarren JA; Rubio R; Norton M;
AIDS; 2008 Jan; 22(2):F1-9. PubMed ID: 18097218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
